TCR2 gains on first signs of cell therapy efficacy in solid tumors

The earliest clinical efficacy data for TCR2’s mesothelin-targeted TRuC T cell therapy hint that the engineered TCR T cells may work in solid tumors, where CAR T cells have yet to shine.

Shares of TCR Therapeutics Inc. (NASDAQ:TCRR) gained

Read the full 383 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers